Tairawhiti, New Zealand – Rua Bioscience has entered into an agreement for the sale of its Gisborne manufacturing facility for $1.3 million. The sale is conditional upon assignment of the underlying land lease which is expected to occur.
This strategic move, as previously signalled, aligns with Rua's ongoing commitment to adopting a capital-light business model by outsourcing commercial manufacturing and cultivation, enabling the company to focus on genetic research, development, and global distribution.
The sale to a Tairawhiti based group supports Rua's strategy to streamline operations and reinforce its focus on developing unique cannabis-based medicines for export markets.
Rua continues to advance its mission of creating medicinal cannabis products that change lives, with a focus on sustainable growth and social impact in the communities of Te Tairāwhiti.
ENDS
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
[email protected]
+64 21 445154
The NZX 50 Index closed at 13,070.45, up 139.72 points or 1.08%.
The a2 Milk Company has emerged as the winner of August.
New CEO Karl Gradon says his mandate is ‘very clear’.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details